skip to primary navigationskip to content
 

Camallergy Appoints Baxter Phillips III as CEO

last modified Oct 25, 2018 01:48 PM
Camallergy, based at ideaSpace South, a biopharmaceutical company dedicated to providing patient-centric treatments for life-threatening food allergies, has announced the appointment of Baxter Phillips III as Chief Executive Officer. Camallergy co-founder Sherden Timmins continues his executive appointment in the newly created role of Chief Operating Officer.

Baxter comes to Camallergy with first-hand knowledge of patient well-being for those who suffer from food allergies. Coupled with a strategic executive’s vision of how to build and deliver on our mission to bring the best treatment for patients to market, we believe he is an exceptional addition to our team at Camallergy as we advance into Phase 3 trials,” stated Dr. Jonathan Milner, PhD, Chairman of the Camallergy Board of Directors and co-founder of Abcam. 

Commenting on his appointment Mr. Phillips said: “With life-threatening food allergies in my family, specifically peanut allergy, I have spent the last several years evaluating current treatment options as well as the various treatments in development today. I am thrilled and privileged to join this pioneering team at Camallergy who is developing what I believe to be the most therapeutically attractive solution for peanut allergy patients."

Read the full article here.

RSS Feed Latest news

Young People's Mental Health (YPMH) - 'Changing Minds' report released.

Sep 22, 2020

ideaSpace West member, Cambridge-based charity YPMH has released ‘Changing Minds – a new approach to understanding and treating depression in young people'. Its ambition is to join up different areas of research and practice in order to change the way depression in young people is understood and treated.

Focus on a Founder with Mark Kotter - Celebrating 10 years of Community

Aug 26, 2020

This is the last in the series of ‘Focus on a Founder’. This week we spoke to Mark Kotter of Bit Bio who joined ideaSpace in 2017.

View all news